Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation

Oncotarget

Volumn 7, Issue 21, 2016, Pages 31014-31028

  Fiorentino, Francesco Paolo ^a   Tokgün, Elvan ^a   Solé Sánchez, Sònia ^a   Giampaolo, Sabrina ^a   Tokgün, Onur ^a   Jauset, Toni ^b   Kohno, Takashi ^c   Perucho, Manuel ^a,d   Soucek, Laura ^b,d,e   Yokota, Jun ^a,c  

^a Institute of Predictive and Personalized Medicine of Cancer IMPPC   (Spain)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

CDKN1A; MYC; MYCL; SCLC; Small cell lung cancer

Indexed keywords

MYC PROTEIN; PROTEIN P21; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; MAX PROTEIN, HUMAN; MYC PROTEIN, HUMAN; OMOMYC PROTEIN; PEPTIDE FRAGMENT; PROTEIN P53; RB1 PROTEIN, HUMAN; RETINOBLASTOMA BINDING PROTEIN; TP53 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CDKN1A GENE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE ACTIVATION; GENE AMPLIFICATION; GENE FUNCTION; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MYCL GENE; MYCN GENE; ONCOGENE MYC; RB1 GENE; SMALL CELL LUNG CANCER; TP53 GENE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL DEATH; CELL GROWTH; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL GROWTH PROCESSES; GENE AMPLIFICATION; GENE SILENCING; GENES, P53; GENETIC THERAPY; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA BINDING PROTEINS; SMALL CELL LUNG CARCINOMA; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84971508916     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8826     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90. doi:10.3322/caac.20107.
2. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44:1104-1110. doi:10.1038/ng.2396.
3. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012; 44:1111-1116. doi:10.1038/ng.2405.
4. Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, Tsuta K, Nishikawa R, Noguchi M, Sato-Otsubo A, Ogawa S, Yokota J. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosom Cancer. 2013; 52:802-816. doi:10.1002/gcc.22076.
5. Iwakawa R, Kohno T, Totoki Y, Shibata T, Tsuchihara K, Mimaki S, Tsuta K, Narita Y, Nishikawa R, Noguchi M, Harris CC, Robles AI, Yamaguchi R, Imoto S, et al. Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis. 2015; 36:616-621. doi:10.1093/carcin/bgv026.
6. Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C, Koker M, Richters A, Heynck S, Malchers F, Heuckmann JM, Seidel D, Eyers PA, Ullrich RT, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA. 2012; 109:17034-17039. doi:10.1073/pnas.1207310109.
7. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, Cibulskis K, Bhutkar A, McKenna A, Dooley A, Vernon A, Sougnez C, Malstrom S, Heimann M, Park J, et al. Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. Cell. 2014; 156:1298-1311. doi:10.1016/j.cell.2014.02.031.
8. Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, Berns A. A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer. Cancer Cell. 2011; 19:244-256. doi:10.1016/j.ccr.2010.12.021.
9. Ookawa K, Shiseki M, Takahashi R, Yoshida Y, Terada M, Yokota J. Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene. 1993; 8:2175-2181.
10. Adachi J, Ookawa K, Kohno T, Tomizawa Y, Tsuchida S, Yokota J. Phenotypic alterations of small cell lung carcinoma induced by different levels of wild-type p53 expression. Cell Death Differ. 1998; 5:148-155.
11. Wu C-H, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA. 2007; 104:13028-13033. doi:10.1073/pnas.0701953104.
12. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA. 2006; 103:16266-16271. doi:10.1073/pnas.0608017103.
13. Felsher DW. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer. 2010; 1:597-604. doi:10.1177/1947601910377798.
14. Ikegaki N, Minna J, Kennett RH. The human L-myc gene is expressed as two forms of protein in small cell lung carcinoma cell lines: detection by monoclonal antibodies specific to two myc homology box sequences. The EMBO Journal. 1989; 8:1793-1799.
15. Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harbor Perspectives in Medicine. 2014; 4:a014357-a014357. doi:10.1101/cshperspect.a014357.
16. Wu S, Cetinkaya C, Munoz-Alonso MJ, Lehr von der N, Bahram F, Beuger V, Eilers M, Leon J, Larsson L-G. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003; 22:351-360. doi:10.1038/sj.onc.1206145.
17. Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M. MAX Inactivation in Small Cell Lung Cancer Disrupts MYCSWI/SNF Programs and Is Synthetic Lethal with BRG1. 2014; 4:292-303. doi:10.1158/2159-8290.CD-13-0799.
18. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998; 17:2463.
19. Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S. Omomyc, a potential Myc dominant negative, enhances Mycinduced apoptosis. Cancer Research. 2002; 62:3507-3510.
20. Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S. The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy. PLoS ONE. 2011; 6:e22284. doi:10.1371/journal.pone.0022284.g009.
21. Soucek L, Nasi S, Evan GI. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004; 11:1038-1045. doi:10.1038/sj.cdd.4401443.
22. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. Modelling Myc inhibition as a cancer therapy. Nature. 2008; 455:679-683. doi:10.1038/nature07260.
23. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes & Development. 2013; 27:504-513. doi:10.1101/gad.205542.112.
24. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes & Development. 2011; 25:907-916 doi:10.1101/gad.2038411.
25. Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu M-E, Swigart LB, Mc Gee MM, et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun. 2014; 5:4632. doi:10.1038/ncomms5632.
26. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Developmental Cell. 2008; 14:159-169. doi:10.1016/j.devcel.2008.01.013.
27. Fiorentino FP, Symonds CE, Macaluso M, Giordano A. Senescence and p130/Rbl2: a new beginning to the end. Cell Res. 2009; 19:1044-1051. doi:10.1038/cr.2009.96.
28. Naruse I, Hoshino H, Dobashi K, Minato K, Saito R, Mori M. Over-expression of p27kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int J Cancer. 2000; 88:377-383. doi:10.1002/1097-0215(20001101)88:3<377::AIDIJC9> 3.0.CO;2-M.
29. Seoane J, Le H-V, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002; 419:729-734. doi:10.1038/nature01119.
30. Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat. 2014; 35:702-714. doi:10.1002/humu.22523.
31. Watanabe KI. Physical Interaction of p73 with c-Myc and MM1, a c-Myc-binding Protein, and Modulation of the p73 Function. Journal of Biological Chemistry. 2002; 277:15113-15123. doi:10.1074/jbc.M111281200.
32. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483:603-307. doi:10.1038/nature11003.
33. Wang H, Prochownik EV. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 2008; 27:1905-1915. doi:10.1038/sj.onc.1210823.
34. Biroccio A, Amodei S, Antonelli A, Benassi B, Zupi G. Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J Biol Chem. 2003; 278:35693-35701. doi:10.1074/jbc. M304597200.
35. Zirath H, Frenzel A, Oliynyk G, Segerström L, Westermark UK, Larsson K, Munksgaard Persson M, Hultenby K, Lehtiö J, Einvik C, Påhlman S, Kogner P, Jakobsson P-J, Henriksson MA. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci USA. 2013; 110:10258-10263. doi:10.1073/pnas.1222404110.
36. Kim T, Jeon Y-J, Cui R, Lee J-H, Peng Y, Kim S-H, Tili E, Alder H, Croce CM. Role of MYC-Regulated Long Noncoding RNAs in Cell Cycle Regulation and Tumorigenesis. J Natl Cancer Inst. 2015; 107:dju505-dju505. doi:10.1093/jnci/dju505.
37. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009; 9:400-414. doi:10.1038/nrc2657.
38. Eilers M, Eisenman RN. Myc's broad reach. Genes & Development. 2008; 22:2755-2766. doi:10.1101/gad.1712408.
39. Hermeking H, Funk JO, Reichert M, Ellwart JW, Eick D. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene. 1995; 11:1409-1415.
40. Uramoto H. p73 Interacts with c-Myc to Regulate Y-boxbinding Protein-1 Expression. Journal of Biological Chemistry. 2002; 277:31694-31702. doi:10.1074/jbc.M200266200.
41. Muppani N, Nyman U, Joseph B. TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death. Oncotarget. 2011; 2:1145-1154. doi: 10.18632/oncotarget.391.
42. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park K-S, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524:47-53. doi:10.1038/nature14664.
43. Huang M-J, Cheng Y-C, Liu C-R, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Experimental Hematology. 2006; 34:1480-1489. doi:10.1016/j. exphem.2006.06.019.
44. Wang J, Ma X, Jones HM, Chan LL-Y, Song F, Zhang W, Bae-Jump VL, Zhou C. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. Journal of Translational Medicine. 2014; 12:226. doi:10.1186/s12967-014-0226-x.
45. D'Agnano I, Valentini A, Fornari C, Bucci B, Starace G, Felsani A, Citro G. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels. Oncogene. 2001; 20:2814-2825. doi:10.1038/sj.onc.1204392.
46. Xue Jun H, Gemma A, Hosoya Y, Matsuda K, Nara M, Hosomi Y, Okano T, Kurimoto F, Seike M, Takenaka K, Yoshimura A, Toyota M, Kudoh S. Reduced transcription of theRB2/p130 gene in human lung cancer. Mol Carcinog. 2003; 38:124-129. doi:10.1002/mc.10152.
47. Fiorentino FP, Macaluso M, Miranda F, Montanari M, Russo A, Bagella L, Giordano A. CTCF and BORIS Regulate Rb2/p130 Gene Transcription: A Novel Mechanism and a New Paradigm for Understanding the Biology of Lung Cancer. Molecular Cancer Research. 2011; 9:225-233. doi:10.1158/1541-7786.MCR-10-0493.
48. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, Karnezis AN, Sweet-Cordero EA, Sage J. Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma. Cancer Research. 2010; 70:3877-3883. doi:10.1158/0008-5472. CAN-09-4228.
49. Pantoja C, Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene. 1999; 18:4974-4982. doi:10.1038/sj.onc.1202880.